Novartis Ag (NVS) Cash from Financing Activities (2009 - 2026)

Novartis Ag has reported Cash from Financing Activities for 18 years, with the latest figure at -$2.0 billion in Q2 2026.

• Quarterly Cash from Financing Activities rose 61.25% year-over-year to -$2.0 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$16.0 billion (up 6.88% YoY) and the FY2025 annual result came in at -$14.9 billion, down 26.61% from the prior year.
• Cash from Financing Activities climbed to -$2.0 billion in Q2 2026 per NVS's latest filing, from -$5.2 billion in the prior quarter.
• Over five years, Cash from Financing Activities peaked at -$382.0 million in Q3 2024 and troughed at -$8.4 billion in Q4 2024.
• A 5-year average of -$3.2 billion and a median of -$2.8 billion in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2024 and 2026: Cash from Financing Activities plunged 1586.29% in 2024, then jumped 61.25% in 2026.
• Over 5 years, Cash from Financing Activities stood at -$2.3 billion in 2022, then soared by 78.45% to -$496.0 million in 2023, then slumped by 1586.29% to -$8.4 billion in 2024, then surged by 37.67% to -$5.2 billion in 2025, then surged by 61.25% to -$2.0 billion in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$2.0 billion, -$5.2 billion, and -$8.4 billion for Q2 2026, Q2 2025, and Q4 2024 respectively.